Ankyra
Company

Last deal

$45.M

Amount

Series B

Stage

12.11.2021

Date

2

all rounds

$59.5M

Total amount

General

About Company
Ankyra is developing a platform to improve the safety and efficacy of cytokine immunotherapies for cancer.

Industry

Sector :

Subsector :

Keywords :

Also Known As

Ankyra Therapeutics

founded date

01.01.2019

Number of employees

Last funding type

Series B

IPO status

Private

Description

Ankyra provides cancer therapy services that use tumor localized immune potentiating agents to boost anti-tumor immune responses. Their approach, called Anchored Immunotherapy, promotes prolonged immune activation locally while limiting systemic toxicity. This allows for systemic dosing of immune stimulants that were previously limited by broad immune activation and toxicity. Ankyra's goal is to provide cancer patients with an instant treatment for cancer without any surgery.
Contacts

Phone number

Social url